Methionine As an Additive to Cassava Based Diets In

Total Page:16

File Type:pdf, Size:1020Kb

Methionine As an Additive to Cassava Based Diets In IDRC-095e CASSAVA AS ANIMAL FEED Proceedings of a workshop held at the University of Guelph, 18-20 April1977 Editors: Barry N estel and Michael Graham Cosponsored by the International Development Research Centre and the University of Guelph © 1977 International Development Research Centre Postal Address: Box 8500, Ottawa, Canada K1G 3H9 Head Office: 60 Queen Street, Ottawa Neste!, B. Graham,M. IDRC University of Guelph IDRC-095e Cassava as animal feed: proceedings of a workshop held at the University of Guelph, 18-20 April 1977. Ottawa, IDRC, 1977. 147p. tables. /IDRC pub CRDI/. Compilation of workshop papers on the use of I cassava/-based I feed/ s-discusses methionine I amino acid/ supple­ mentation of cassava diets; metabolic pathways and their significance in I animal nutrition/; single-cell I protein/ production (use of I bacteria/ to convert cassava into microbial protein); I animal feeding/ systems for I swine/, I poultry I and I cattle/; I feed production/ techniques such as pelleting. I List of participants/, I statistical data/. UDC: 636.085 ISBN: 0-88936-142-8 Microfiche Edition $1 Contents 5 Foreword 7 Participants 9 Methionine as an additive to cassava-based diets A. A. Adegbola 18 Additives other than methionine in cassava diets R.I. Hutagalung 33 Physiological and biochemical responses of rats given potassium cyanide or linamarin D. C. Hill 43 Cassava in the nutrition of broilers J. J. Montilla 51 Cassava in the nutrition of layers T. A. Omole 56 Cassava in the nutrition of swine S. Khajarern, J. M. Khajarern, N. Kitpanit, and Z. 0. Miiller 65 Life-cycle swine feeding systems with cassava G. Gomez 72 Cassava as a substrate for single-cell protein production: microbiological aspects K. F. Gregory 79 Fermentor performance in microbial protein production from cassava A. G. Meiering and F. A. Azi 85 Laboratory animal nutrition with fungi grown on cassava J. C. Alexander 91 Pilot plant for single-cell protein production J. Santos N. and G. Gomez 95 Whole plant utilization of cassava for animal feed A. Montaldo 107 Cassava as a feed source for ruminants C. Devendra 120 Improving the quality of cassava root and leaf product technology Z. Miiller 127 Discussion conclusions 131 Bibliography 3 Methionine as an Additive to Cassava-Based Diets A. A. Adegbola 1 Methionine is required by animals for the synthesis of proteins, as a major source of methyl groups, and in cassava-based rations, it serves as a source of sulfate ions for the purpose of detoxication. It shares this role with other sulfur-donors such as cystine, thiosulfate, and elemental sulfur. The amino acid patterns of cassava leaf meal and cassava root meal show a deficiency of methionine. Added methionine may be required to improve the quality and utilization of dietary protein. In a properly· balanced diet, additional methionine may be required primarily for the detoxication of prussic acid released in the hydrolysis of linamarin and lotaustralin. Levels of 0.2-0.3% methionine, for poultry, and 0.2% methionine for pigs have been used in rations for these species and positive responses in terms of growth perform­ ance have been obtained in most cases. Attention is drawn to the need to relate responses to added methionine in rations to the levels of protein in the diet as well as to the physical nature and palatability of the feed. There is a need to relate the results of added methi­ onine to the levels of cysteine plus methionine in order to further explain the contradictory observations on urinary thiocynanate, particularly in swine. Methionine is an essential amino acid, and down of homocysteine, serine and/ or glycine like other amino acids its primary role in nutri­ are required to form cystathionine, which then tion is for the synthesis of proteins. Animals breaks down irreversibly to cysteine and are dependent on their food for their supply of cystine, the other sulfur containing amino methionine. Body requirements for methionine, acids. The final oxidation of these latter acids like other amino acids, can be influenced by results in the production of sulfate ion, pyru­ other dietary factors such as level of protein, vate, and ammonia. energy, vitamin B12, folate, and the levels of If the main rational for supplementing cas­ certain other amino acids. In this regard, the sava diets with methionine is as a source of level of cystine and/ or cysteine in animal diets sulfate ions for the purpose of detoxication is of importance and the usual consideration of the cyanide present in food, then from the appears to be for a combined requirement of purely biochemical point of view, this role of the sulfur-containing amino acids, a proportion detoxication cannot be a property of methio­ of which must be methionine in animal diets. nine alone but of all sulfur containing amino A consideration of the metabolism of acids. Olson et al. ( 1969) 2 obtained results that methionine indicates its other role in nutrition demonstrated that supplementation of cassava as that of a major source of methyl groups in chick diets with 0.2% methionine gave equal the body. In its active form of S-adenosyl­ performance to 0.4 or 0.8% cystine addition methionine, methyl groups can be transferred to the diet. Methionine may, however, be pre­ for example to guanidoacetic acid to form ferred as an additive because it is an essential creatine or to nicotinamide to form N-methyl­ amino acid and when metabolized it yields nicotinamide or to phosphadidyl-ethanolamine cystine and cysteine and can thus be a source to form lecithine and to a number of other of these sulfur-containing amino acids where substrates to form other products required for these are deficient. Generally, livestock rations various body processes. The residue of these based on cassava roots and leaves have used methylation reactions is usually S-adenosyho­ soybean meal and groundnut cake as sources mocysteine, which is then cleaved to adenosine of protein. These two protein concentrates are and homocysteine. For the complete break- 2AJJ references in this monograph have been !Department of Animal Science, University of combined to form a comprehensive literature re­ Ife, Ile-Ife, Nigeria. view (seep. 131). 9 10 CASSAVA AS ANIMAL FEED deficient in methionine. Added methionine stimulate growth even when supplemented with therefore helps to improve the protein quality lysine, methionine, and threonine. Further, of the rations. Pecknik and Guimaraes ( 1963) prepared meals from sweet cassava leaves dried at room temperature (25 oc) and in a refrigerator Protein Quality of Cassava (5 oc). They concluded that the diet contain­ To understand the effect of adding amino ing material dried at 5 oc proved to be supe­ acids to cassava-based rations, it is useful to rior, except when supplemented with lysine examine the quality of the protein in cassava and histidine. The best growth response was roots and leaves. Rao et al. (1951) analyzed produced with diets supplemented with purified tapioca protein with an ash content methionine alone and the minimal amount re­ of 1.03% for nitrogen ( 10.5% ) and for amino quired to produce optimal feed efficiency was acids (calculated on g/16 g N basis) . The ap­ 0.3%. proximate composition was arginine 8.2, his­ Eggum (1970) fed rats diets in which all the tidine 3.5, tyrosine 1.3, tryptophan 1. 7, cystine N was derived from the protein of leaves of 2.6; the sample contained no methionine. Simi­ three cassava cultivars and reported an average larly, FAO in 1970 noted that cassava meal true digestibility of 72.97%, a low biological contained only 22 mg/1 00 g of methionine value of 53.37%, a much lower net protein (compared with 182 mg/1 00 g for maize) and utilization of 38.93%, and utilizable nitrogen that cassava was generally deficient in the sul­ of 2.17%. fur amino acids. Amino acid profiles of cassava leaves by The effect of heat treatment on the pro­ Eggum (1970) and Rogers and Milner (1963) tein quality of cassava leaves was investigated indicate a low content of methionine and by Pechnik and Guimaraes ( 1962). Meals pre­ cystine in the leaf protein (Table 1 ) . Ross and pared from leaves dried at room temperature Enrique ( 1969) also estimated the level of promoted growth of Wistar rats at a slow, sub­ methionine in cassava leaf meal to range be­ normal rate, while meal obtained from leaves tween 0.25 and 0.32% and that of cystine as dried at 70-80 oc for 24 h produced no growth 0.18-0.23% as fed. The content of other essen­ response unless the diet was supplemented with tial amino acids appears to be adequate, es­ methionine and lysine. When the meal was pecially that of lysine for chick diets. prepared with cassava leaves dried at 70- When 50% of the nitrogen was supplied by 80 oc for 24 h. boiled, and redried, it did not dried cod fish and 50% by cassava leaf, the Table 1. Amino acid profiles (%) for cassava leaf protein dry matter (Rogers and Milner 1963; Eggum 1970). Average for NRC Jamaican Brazilian Nigerian all samples requirements samples samples , samples (as fed) for chicks (average) (average) (average) 20% of diet (0-6 wks) Arginine 5.54 6.49 5.89 1.18 1.2 Glycine 5.66 5.64 5.55 1.10 1.0 and/or Serine 5.42 4.88 5.31 0.27 Histidine 2.34 2.71 2.60 0.50 0.4 Isoleucine 5.26 5.13 5.04 1.01 0.75 Leucine 9.33 9.38 9.29 1.83 1.4 Lysine 7.56 6.71 6.64 1.37 1.1 Methionine 1.73 1.81 2.13 0.37 0.75(or0.40) Cystine 1.44 1.10 1.65 0.27 0.35 Phenylalanine 6.11 5.86 5.64 1.15 1.3 (or 0.
Recommended publications
  • Thiosulfate De Sodium Sterop
    Thiosulfate de Sodium Sterop 1. DENOMINATION DU MEDICAMENT THIOSULFATE DE SODIUM STEROP 1g/5ml solution injectable 2. COMPOSITION QUALITATIVE ET QUANTITATIVE Substance active : Une ampoule de 5ml contient 1g de thiosulfate de sodium dans de l’eau pour préparations injectables. 1 ml de solution contient 200mg de thiosulfate de sodium. Pour la liste complète des excipients, voir rubrique 6.1. 3. FORME PHARMACEUTIQUE Solution injectable. 4. DONNEES CLINIQUES 4.1 Indications thérapeutiques - Antidote dans le traitement des intoxications par les cyanures ainsi que par le nitroprussiate de sodium. - Prévention des effets néphrotoxiques du cisplatine. Thiosulfate de Sodium Sterop © Pharma.be Pagina 1 van 6 4.2 Posologie et mode d’administration Mode d'administration Pour voie intraveineuse lente. Posologie Intoxications par les cyanures: Adultes: La posologie habituelle est de 12,5 g de thiosulfate de sodium, administré par voie I.V. sur une période de 5 à 10 minutes. Enfants: La posologie habituelle est de 412,5 mg de thiosulfate de sodium par kg, administré par voie I.V. à la vitesse de 0,625 à 1,25 g/minute sur une période de 5 à 10 minutes. Si les symptômes persistent ou réapparaissent dans la demi-heure ou dans l’heure ayant suivi la première injection, une seconde injection de thiosulfate de sodium est nécessaire avec comme posologie la moitié de celle de la première injection. En prévention des effets néphrotoxiques du cisplatine: Chez l'adulte, la posologie initiale est de 9 g de thiosulfate de sodium par m2 de surface corporelle, administré par voie I.V. Elle est suivie par l'injection de 1,2 g de thiosulfate de sodium par m2 de surface corporelle par heure, en perfusion I.V.
    [Show full text]
  • Adult BLS Standing Orders • Ensure EMS Provider Safety, Consider HAZMAT Activation
    Imperial County Public Health Department Emergency Medical Services Agency Policy/Procedure/Protocol Manual Treatment Protocols Date: 07/01/2021 Poisoning/Intoxication/Envenomation - Adult Policy #9160A Adult BLS Standing Orders • Ensure EMS provider safety, consider HAZMAT activation. Recognize, Notify, Isolate • Universal Patient Protocol • Do not approach patient or location if scene safety is in question • Obtain accurate history of incident: o Name of product or substance o Quantity ingested, and/or duration of exposure o Time elapsed since exposure o If safe and accessible, bring medications or bottles to hospital • Move victim(s) to safe environment • Externally decontaminate - PRN • Continuously monitor ECG, blood pressure, pulse oximetry, and capnography (if ALS present) PRN • Give oxygen and provide airway support per Airway Policy • Contact Poison Control Center as needed 1 (800) 222-1222 Suspected Opioid Overdose with Respirations <12 RPM • If possible, avoid the use of a supraglottic device prior to the administration of naloxone • Administer naloxone 0.1 mg/kg, max of 2 mg IN. May repeat up to three (3) times, q5min • May assist family/friends on-scene with administration of patient’s own naloxone • NOTE - Use with caution in opioid dependent pain management patients • Assess vitals, with specific attention to respiratory rate and respiratory drive • Note pupil exam • Note drug paraphernalia or medication bottles near patient Suspected Stimulant Overdose with Sudden Hypoventilation, Oxygen Desaturation, or Apnea • High flow
    [Show full text]
  • Hydrogen Sulfide Metabolite, Sodium Thiosulfate
    International Journal of Molecular Sciences Review Hydrogen Sulfide Metabolite, Sodium Thiosulfate: Clinical Applications and Underlying Molecular Mechanisms Max Y. Zhang 1,2, George J. Dugbartey 1,2,3, Smriti Juriasingani 1,3 and Alp Sener 1,2,3,4,* 1 Matthew Mailing Center for Translational Transplant Studies, London Health Sciences Center, Western University, London, ON N6A 5A5, Canada; [email protected] (M.Y.Z.); [email protected] (G.J.D.); [email protected] (S.J.) 2 London Health Sciences Center, Multi-Organ Transplant Program, Western University, London, ON N6A 5A5, Canada 3 London Health Sciences Center, Department of Surgery, Division of Urology, Western University, London, ON N6A 5A5, Canada 4 Department of Microbiology & Immunology, Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON N6A 3K7, Canada * Correspondence: [email protected]; Tel.: +1(519) 6633352 Abstract: Thiosulfate in the form of sodium thiosulfate (STS) is a major oxidation product of hydrogen sulfide (H2S), an endogenous signaling molecule and the third member of the gasotransmitter family. STS is currently used in the clinical treatment of acute cyanide poisoning, cisplatin toxicities in cancer therapy, and calciphylaxis in dialysis patients. Burgeoning evidence show that STS has antioxidant and anti-inflammatory properties, making it a potential therapeutic candidate molecule that can target multiple molecular pathways in various diseases and drug-induced toxicities. This review Citation: Zhang, M.Y.; Dugbartey, discusses the biochemical and molecular pathways in the generation of STS from H2S, its clinical G.J.; Juriasingani, S.; Sener, A. usefulness, and potential clinical applications, as well as the molecular mechanisms underlying these Hydrogen Sulfide Metabolite, clinical applications and a future perspective in kidney transplantation.
    [Show full text]
  • Ingestions, Intoxications, and the Critically Ill Child Poisoning in Children
    Ingestions, Intoxications, and the Critically Ill Child Poisoning in Children • 1 million cases of exposure to toxins in children younger than 6 years reported in the U.S. In 1993 • estimated that another 1 million exposures to toxins not reported • 1% have moderate or major life-threatening symptoms • 60-100 deaths annually in the U.S Poisoning in Children Less Than 5 Years Old • accounts for 85-90% of pediatric poisoning • is generally accidental • secondary to exploratory behavior and lack of supervision • tend to involve single agent ingestions Poisoning in Children Over 5 Years Old • accounts for 10-15% of pediatric poisoning • is generally intentional • secondary to suicide attempts or gestures, or to intoxications and inadvertent overdose • tend to involve multiple agent ingestions General Concepts for Pediatric Poisoning • Prevention • Initial Stabilization • Diagnosis • Specific Antidotes Management of the Poisoned Child • Treat the Patient, Not the Poison --patient-specific treatment is safer, less expensive, and more effective Management of the Poisoned Child • Stabilization --Airway --Breathing --Circulation --Disability (neurologic) Management of the Poisoned Child • Respiratory Failure --airway obstruction from secretions, refluxed gastric contents, airway muscle relaxation --respiratory muscle rigidity --loss of respiratory drive --pulmonary edema Management of the Poisoned Child • Cardiovascular Collapse --arteriolar dilation --venous dilation --myocardial depression --dysrhythmias Management of the Poisoned Child • Neurologic
    [Show full text]
  • Antidote List
    Antidote List Recommended minimum amounts for hospital pharmacies to stock Call the Maryland Poison Center for expert advice on the treatment of all poisonings and overdoses: 1-800-222-1222 Poisoning Minimum Stocking Antidote Indication Recommendations Oral: 120 grams Acetylcysteine Acetaminophen IV: 96 grams Crotaline snake Antivenin, snake (CroFab®) 12 vials envenomation 1 vial Black widow spider (Note: Merck limits distribution Antivenin, black widow spider envenomation to cases of confirmed bites with symptoms only) Organophosphate & Atropine carbamate insecticides, nerve 165 mg gases Calcium chloride Calcium channel blockers 10 grams 2.25 grams Calcium disodium EDTA Lead (Available direct from ASD Specialty Healthcare) Hydrofluoric acid 1 kg (powder) Calcium gluconate Calcium channel blockers IV: 30 grams 1 kit Cyanide Antidote Kit Cyanide (or Hydroxocobalamin, see below) Cyproheptadine (Periactin®) Serotonin syndrome 80 mg Neuroleptic malignant Dantrolene syndrome, stimulant-induced 720 mg hyperthermia Deferoxamine mesylate Iron 8 grams (Desferal®) Digoxin Immune FAB Digoxin 20 vials (Digibind®, DigiFab®) Dimercaprol (BAL) Heavy metals 1.5 grams 1 | P a g e Maryland Poison Center Antidote List – continued Poisoning Minimum Stocking Antidote Indication Recommendations DMSA (Succimer, Chemet®) Heavy metals 2000 mg Folic acid Methanol IV: 150 mg Flumazenil (Romazicon®) Benzodiazepines 10 mg Fomepizole (Antizol®) Ethylene glycol, methanol 12 grams Beta blockers, Glucagon 50 mg calcium channel blockers Hydroxocobalamin (Cyanokit®) Cyanide
    [Show full text]
  • Antidote Stocking Tier C
    These Tier C recommendations are general To Contact your Regional Poison Center: (800) 222-1222 Consultation is available by a Specialist in Poison Information or Toxicologist (upon request) 24 hours daily. Toxin Current Recommended Antidote Dosing Other Info Stock Stock Indicated for moderate to severe envenomations Moderate: Evidence of local tissue injury that extends 1 4-6 vials IV q2-4h Antivenin Snake bite major joint proximal to bite until pain improves, Crotalidae (Copperhead, and/or numeric coagulopathy 12 vials swelling stops, or Polyvalent Immune Water without clinical bleeding clinical bleeding FAB moccasins, resolves, then 2 vials (CroFab™) Rattlesnakes) Severe: Local injury >1 joint, q6h for 3 doses documented compartment syndrome, coagulopathy with clinical bleeding, hypotension, angioedema, and/or neurological findings None (currently must be drop-shipped based Antivenin-black Black Widow 1 vial in 50 ml of NS Equine derived antivenom on patient presentation widow envenomation – black widows not likely in western KY) Organo- 2-4 mg IV q5-10 phosphate or minutes or 0.02- carbamate Indicated for SLUDGE 5 x 20 ml (0.4 mg/ml) 0.08 mg/kg/hr IV Atropine pesticides symptoms associated with vials infusion until and cholinergic excess excessive bronchial muscarine secretions terminate mushrooms These Tier C recommendations are general To Contact your Regional Poison Center: (800) 222-1222 Consultation is available by a Specialist in Poison Information or Toxicologist (upon request) 24 hours daily. Antidote Current Recommended Toxin
    [Show full text]
  • Dialyzability of Medications During Intermittent Hemodialysis
    DialyzeIHD: Dialyzability of Medications During Intermittent Hemodialysis % Dialyzed % Dialyzed % Dialyzed % Dialyzed IHD Dosing; Administration IHD Dosing; Administration IHD Dosing; Administration IHD Dosing; Administration Timing Drug (Type of Drug (Type of Drug (Type of Drug (Type of Timing Around HD Session Timing Around HD Session Around HD Session Dialyzer) Timing Around HD Session Dialyzer) Dialyzer) Dialyzer) 0.25-0.5mg PO Q8H PRN, Insulin Aspart, Pentamidine 0 4mg/kg IV Q24-36H, Not recommended for use, Clonazepam N/A Reduce to 25-50% of normal dose Acarbose N/A Administer anytime during HD Insulin Detemir, Isethionate (N/A) Administer anytime during HD Administer anytime during HD N/A and titrate, Administer anytime Insulin Glargine, 0.1-0.4mg PO Q8-12H, during HD Normal dose and titrate based on 100-150mg PO Q12-24H, <5 Insulin Lispro Acebutolol N/A Clonidine Administer anytime during HD; No target free or corrected total Administer post-HD (Low Flux) Phenytoin Dose post-HD if hypotensive 75-300mg PO Q24H, (Low Flux) phenytoin level, Normal dose based on indication, 0 Administer anytime during HD Acetaminophen N/A 75mg PO Q24H, Irbesartan Administer anytime during HD; Dose Administer anytime during HD Clopidogrel N/A (N/A) Administer anytime during HD post-HD if hypotensive No 15-45mg PO Q24H, Pioglitazone 2.5-5mg/kg IV/PO Q24H, (N/A) Administer anytime during HD 40-60 250-500mg PO Q6H or 1-2g IV Q4- 100mg IV weekly to monthly, Acyclovir Administer post-HD over 60 Cloxacillin N/A Iron Dextran N/A (N/A) 6H, Administer anytime
    [Show full text]
  • Essential Medications Review
    Essential medications for high-quality patient care Quarter 3 2021 update Essential medications – September 2021 As part of the mission to end drug shortages, the Vizient team of pharmacy experts continues to identify essential medications where, if not available, would prove the greatest threat to hospitals’ ability to provide immediate and high-quality patient care. Medications identified as of greatest importance were selected by the Vizient pharmacy team from a comprehensive clinical review of products contained within the World Health Organization’s (WHO) Essential Medicines list, the Advanced Cardiac Life Support (ACLS) and Pediatric Advanced Life Support (PALS) algorithms, and medications included in Vizient member health systems’ critical drug lists. As of this edition, 14 drugs were added to the list creating a total of 251 line items, representing 237 unique drugs and three categories. This includes: • Acute treatment drugs with no alternatives (77 drugs) – Medicines used in acute and critical circumstances to sustain life and for which there are no current alternatives • Chronic treatment drugs with no alternatives (37 drugs) – Products used in chronic disease states or conditions where no alternatives are available (e.g., chemotherapy medications) • High impact drugs (137 drugs) – Medicines for which alternatives are available but may be less clinically desirable and/or are more operationally difficult to use; also reflects drugs where the absence of one medication can affect therapeutically related drugs. Updated quarterly,
    [Show full text]
  • Poison Control Antidote Poster
    Antidote Chart (The suggested minimum stocking level is a combination of factors; anticipation of the highest total dose of a drug generally given during a 24 hour period to a 70 kg adult.) General Decontamination Uses Dose Comments Activated Charcoal (without sorbitol) Most ingestions occurring within one hour Adults: 25–100 grams, Children: 1 g/kg May be given in multiple doses depending on ingestant to enhance elimination Activated Charcoal (with sorbitol) May be used as first AC given to patient if presents within Adults: 25–50 grams Should not be used for multiple dose activated charcoal regimens one hour of ingestion Children: Not generally recommended Whole Bowel Irrigation Drugs not bound by charcoal, sustained Adults: 500–2000 ml/hour Nasogastric tube should be used to maintain amount given (Polyethylene Glycol) release formulations, and body stuffers Children: 25 ml/kg/hour Syrup of Ipecac No longer recommended No longer recommended No longer recommended Poisoning Antidote Quantity to Stock* Comments Acetaminophen N-ACETYLYCYSTEINE 10–20% 600 ml (20% Mucomyst®) Because vomiting of the oral NAC is common, the facility should maintain a repeat dose (Mucomyst®) or 1200 ml (10% Mucomyst®) for each patient for initial dosing if continuation of treatment at facility is not anticipated. ACETADOTE® The IV Acetadote® was just approved in February 2004. Call the MAPCC for dosing, ACETYLCYSTEINE Injection for IV use 4 (30 ml) vials of 20% solution precautions and contraindications. Both the oral and IV forms of acetylcysteine should be administered within 8 hours for maximal protection against hepatic injury. Anticholinergic Poisoning PHYSOSTIGMINE (Antilirium®) 2–4 mg* Not generally recommended for children.
    [Show full text]
  • Toxic Exposure / Poisoning / Overdose
    TOXIC EXPOSURE / POISONING / OVERDOSE GENERAL CONSIDERATIONS A. Consider the possibility of accidental or self-poisoning under the following conditions: 1. History of observed or admitted accidental or intentional ingestion 2. Coma of unknown origin 3. History of suicide gesture or attempt 4. Intoxicated behavior (hyperactive, hypoactive, unstable gait, lethargic, slurred speech) 5. Patients with altered mental status, particularly with bizarre behavior B. Scene safety is your primary concern. Potential threats include: 1. Violent, agitated behaviors from the patient 2. Possibility of the EMT becoming contaminated by the substance C. If suspected HazMat or WMD exposure: 1. Initial PPE should be Level A. 2. EMS personnel will NOT approach the victim without donning appropriate PPE or the victim has received emergency decontamination. D. Emergency decontamination procedures should be initiated whenever a victim has been exposed to a solid or liquid agent or the agent is unknown. With known agents, follow PPE and decontamination recommendations based on research. Emergency decontamination procedures should include: 1. Removal of all clothing, including undergarments 2. Body flushed with large quantities of water 3. Evacuation to an isolated area away from the agent release E. With known or suspected chemical / WMD exposure, contact Medical Control early and advise of the situation. F. EMS should consider the confirmed or potential release of a nerve agent when responding to an unspecified incident or scene involving: 1. An unknown illness involving a potentially large number of patients 2. An explosion from an unknown source at an event where a large number of people are in attendance 3. An incident where the initial EMS responders on scene suddenly become symptomatic 4.
    [Show full text]
  • Chemical Compatibility Storage Group
    CHEMICAL SEGREGATION Chemicals are to be segregated into 11 different categories depending on the compatibility of that chemical with other chemicals The Storage Groups are as follows: Group A – Compatible Organic Acids Group B – Compatible Pyrophoric & Water Reactive Materials Group C – Compatible Inorganic Bases Group D – Compatible Organic Acids Group E – Compatible Oxidizers including Peroxides Group F– Compatible Inorganic Acids not including Oxidizers or Combustible Group G – Not Intrinsically Reactive or Flammable or Combustible Group J* – Poison Compressed Gases Group K* – Compatible Explosive or other highly Unstable Material Group L – Non-Reactive Flammable and Combustible, including solvents Group X* – Incompatible with ALL other storage groups The following is a list of chemicals and their compatibility storage codes. This is not a complete list of chemicals, but is provided to give examples of each storage group: Storage Group A 94‐75‐7 2,4‐D (2,4‐Dichlorophenoxyacetic acid) 94‐82‐6 2,4‐DB 609-99-4 3,5-Dinitrosalicylic acid 64‐19‐7 Acetic acid (Flammable liquid @ 102°F avoid alcohols, Amines, ox agents see SDS) 631-61-8 Acetic acid, Ammonium salt (Ammonium acetate) 108-24-7 Acetic anhydride (Flammable liquid @102°F avoid alcohols see SDS) 79‐10‐7 Acrylic acid Peroxide Former 65‐85‐0 Benzoic acid 98‐07‐7 Benzotrichloride 98‐88‐4 Benzoyl chloride 107-92-6 Butyric Acid 115‐28‐6 Chlorendic acid 79‐11‐8 Chloroacetic acid 627‐11‐2 Chloroethyl chloroformate 77‐92‐9 Citric acid 5949-29-1 Citric acid monohydrate 57-00-1 Creatine 20624-25-3
    [Show full text]
  • Medical Uses of Sodium Thiosulfate Patrick L
    McGeer PL, McGeer EG, Lee M. J Neurol Neuromedicine (2016) 1(3): 28-30 Neuromedicine www.jneurology.com www.jneurology.com Journal of Neurology & Neuromedicine Mini Review Open Access Medical uses of Sodium thiosulfate Patrick L. McGeer*, Edith G. McGeer and Moonhee Lee Kinsmen Laboratory of Neurological Research, University of British Columbia, VancouverBC V6T 1Z3, Canada Article Info Background Sodium thiosulfate (Na S O , STS) is an industrial compound Article Notes 2 2 3 Received: May 26, 2016 which has a long history of medical use. Since it is employed as a Accepted: June 21, 2016 food preservative, the general population is widely exposed to this *Correspondence: non-toxic compound. For example, it is typically added to table salt Dr. Patrick L. McGeer at less than 0.1% and to alcoholic beverages at less than 0.0005%. It Kinsmen Laboratory of Neurological Research, University of is generally available as a non-prescription oral product. British Columbia, 2255 Wesbrook Mall, Vancouver, BC V6T 1Z3 Canada One of the early medical uses of STS was in the successful Tel: +1-604-822-7377 1 FAX: +1-604-822-7086 treatment of arsenic, lead, mercury and bismuth poisoning . Halliday E-mail: [email protected] and Sutherland2 described using intravenous STS in a moribund © 2016 McGeer PL. This article is distributed under the terms of case of arsenic poisoning. There was an immediate response with the Creative Commons Attribution 4.0 International License eventual full recovery. Shiels3 described the use of STS to treat chronic lead poisoning at the Mount Ina mine in Australia.
    [Show full text]